| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
VHL
VHL (von Hippel-Lindau), an E3 ubiquitin ligase. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[2].
As a VHL-binding ligand-linker conjugate, (S,R,S)-AHPC-C6-NH2 itself has no intrinsic biological activity; its function is to recruit the VHL E3 ubiquitin ligase complex. The terminal amine is conjugated to a target protein ligand, and the resulting PROTAC can ubiquitinate and degrade the target protein via the proteasome. |
| ln Vivo |
No specific in vivo activity has been reported for this conjugate alone; its in vivo degradation activity is observed only when conjugated to a target protein ligand to form a complete PROTAC molecule. The in vivo efficacy of such a PROTAC is typically evaluated in animal models of disease.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. Its quality is confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥98%. Its binding affinity to VHL is validated as part of a complete PROTAC construct using biophysical methods.
|
| Cell Assay |
N/A; this conjugate is not tested alone in cell-based assays. In a typical protocol for a complete PROTAC, cells are treated with the compound for 4-24 hours. Target protein levels are then quantified by Western blotting or a degradation assay to determine the DC50 (half-maximal degradation concentration).
|
| Animal Protocol |
N/A; no animal studies are performed with the ligand-linker conjugate alone. For in vivo studies of a final PROTAC, the molecule is formulated in a suitable vehicle and administered to animal models. Target engagement and efficacy are measured by protein knockdown and tumor growth inhibition.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 557.75, a molecular formula of C29H43N5O4S, and is typically stored as a solid powder at -20degC for up to 1 year in a dry, dark environment. It is soluble in DMSO. The amine-terminated linker facilitates versatile conjugation with target protein ligands.
|
| Toxicity/Toxicokinetics |
This product is for research and manufacturing use only and is not for human or clinical use. Standard chemical safety precautions should be followed during handling. This product should be stored in a dry, dark place at -20degC to maintain stability.
|
| References | |
| Additional Infomation |
The (S,R,S)-AHPC (hydroxyproline-based) VHL ligand is one of the most commonly used E3 ligase recruiters in PROTAC design due to its high affinity and well-characterized binding mode. The six-carbon alkyl linker provides optimal spacing for ternary complex formation. This conjugate accelerates the creation of next-generation, highly selective targeted protein degraders for therapeutic applications.
|
| Molecular Formula |
C29H43N5O4S
|
|---|---|
| Molecular Weight |
557.747825860977
|
| Exact Mass |
557.303
|
| CAS # |
2306389-03-5
|
| Related CAS # |
(S,R,S)-AHPC-C6-NH2 dihydrochloride;2341796-77-6;(S,R,S)-AHPC-C6-NH2 hydrochloride;2360522-76-3
|
| PubChem CID |
138693510
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
39
|
| Complexity |
814
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCN)O
|
| InChi Key |
MOCAYTDKEHDJAK-MVERNJQCSA-N
|
| InChi Code |
InChI=1S/C29H43N5O4S/c1-19-25(39-18-32-19)21-12-10-20(11-13-21)16-31-27(37)23-15-22(35)17-34(23)28(38)26(29(2,3)4)33-24(36)9-7-5-6-8-14-30/h10-13,18,22-23,26,35H,5-9,14-17,30H2,1-4H3,(H,31,37)(H,33,36)/t22-,23+,26-/m1/s1
|
| Chemical Name |
(2S,4R)-1-[(2S)-2-(7-aminoheptanoylamino)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~179.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.48 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7929 mL | 8.9646 mL | 17.9292 mL | |
| 5 mM | 0.3586 mL | 1.7929 mL | 3.5858 mL | |
| 10 mM | 0.1793 mL | 0.8965 mL | 1.7929 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
